Unique ID issued by UMIN | C000000041 |
---|---|
Receipt number | R000000081 |
Scientific Title | A phase I/II study of percutaneous vertebroplasty (JIVROSG-0202) |
Date of disclosure of the study information | 2005/08/06 |
Last modified on | 2012/09/21 13:21:20 |
A phase I/II study of percutaneous vertebroplasty (JIVROSG-0202)
Percutaneous vertebroplasty for malignant vertebral tumor (JIVROSG-0202)
A phase I/II study of percutaneous vertebroplasty (JIVROSG-0202)
Percutaneous vertebroplasty for malignant vertebral tumor (JIVROSG-0202)
Japan |
Malignant vertebral bone tumor.
Gastroenterology | Hepato-biliary-pancreatic medicine | Pneumology |
Hematology and clinical oncology | Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
Chest surgery | Breast surgery | Obstetrics and Gynecology |
Orthopedics | Urology | Radiology |
Anesthesiology |
Malignancy
NO
To evaluate the safety and efficacy of percutaneous vertebroplasty for malignant vertebral tumors.
Safety,Efficacy
Confirmatory
Explanatory
Phase I,II
Adverse events
Pain evaluated by Visual Analogue Scale (VAS).
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Under local anesthesia and fluoroscopic or CT guidance, a needle is percutaneously inserted into the vertebral body involved by malignant tumor and cement is injected.
Not applicable |
Not applicable |
Male and Female
1) Primary or metastatic malignant tumor in thoracic or lumber vertebral bone.
2) Severe pain adversely influencing on QOL.
3) No involvement into the spinal canal.
4) Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions.
5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3.
6) Expected survival more than 4 weeks.
7) Written informed consent.
1) Bleeding time more than 5 minutes.
2) Fever above 38 degrees Celsius.
3) Cardiac failure requiring medication.
4) Active inflammation in vertebrae
5) Severely collapsed vertebrae (less than one third of normal height).
6) No severe pain (less than 2 of VAS).
7) Unable to keep prone position for 1 hour.
8) Necessity of procedure for more than 5 contiguous vertebral bodies.
9) Necessity of single session procedure for more than 4 vertebral bodies.
10) Severe drug allergy.
11) Pregnancy.
33
1st name | |
Middle name | |
Last name | Ken Kobayashi |
Kanazawa University Graduate School of Medicine
Department of Radiology
13-1, Takaramachi, Kanazawa 920-8641, Japan
076-265-2323
1st name | |
Middle name | |
Last name | Yasuaki Arai |
JIVROSG, Coordinating Office
Division of Diagnostic Radiology, National Cancer Center Hospital
5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan
03-3542-2511
http://jivrosg.umin.jp/
jivrosgoffice@ml.res.ncc.go.jp
Japan Interventional Radiology in Oncology Study Group (JIVROSG)
Ministry of Health, Labour and Welfare
Japan
NO
2005 | Year | 08 | Month | 06 | Day |
http://jivrosg.umin.jp/
Published
http://annonc.oxfordjournals.org/cgi/content/abstract/20/12/1943
Procedures were completed in all 33 patients (42 vertebrae). Thirty days after PVP, two patients died of primary disease progression, but no major adverse reactions (>grade 2) were observed. Response rate was 70% (95% confidence interval 54% to 83%) [61% (n = 20) with SE, 9% (n = 3) with ME, and 30% (n = 10) with NE] and increased to 83% at week 4. Median time to response was 1 day (mean 2.4). Median pain-mitigated survival period was 73 days.
Completed
2002 | Year | 11 | Month | 30 | Day |
2003 | Year | 02 | Month | 01 | Day |
2006 | Year | 04 | Month | 01 | Day |
2006 | Year | 05 | Month | 01 | Day |
2006 | Year | 05 | Month | 01 | Day |
2006 | Year | 10 | Month | 01 | Day |
2005 | Year | 08 | Month | 06 | Day |
2012 | Year | 09 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000081